Personalis (NASDAQ:PSNL) Trading Up 7.4% - Time to Buy?

Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) traded up 7.4% during trading on Wednesday . The company traded as high as $5.80 and last traded at $5.94. 393,724 shares changed hands during trading, a decline of 62% from the average session volume of 1,032,335 shares. The stock had previously closed at $5.53.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. HC Wainwright increased their target price on shares of Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price objective on shares of Personalis in a research note on Thursday, April 10th. Guggenheim assumed coverage on shares of Personalis in a research note on Thursday, May 15th. They issued a "buy" rating and a $6.00 price target for the company. Finally, Craig Hallum assumed coverage on shares of Personalis in a report on Monday, March 17th. They issued a "buy" rating and a $8.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Personalis has a consensus rating of "Buy" and an average target price of $7.67.

Personalis Stock Performance

The company's fifty day moving average is $4.38 and its 200-day moving average is $4.56. The company has a market capitalization of $530.83 million, a PE ratio of -3.58 and a beta of 1.86.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The firm had revenue of $20.61 million during the quarter, compared to the consensus estimate of $17.41 million. On average, sell-side analysts expect that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Personalis

A number of large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in Personalis in the 4th quarter worth approximately $63,000. Olympiad Research LP acquired a new stake in shares of Personalis in the 4th quarter worth $59,000. Raymond James Financial Inc. acquired a new stake in shares of Personalis in the 4th quarter worth $64,000. American Century Companies Inc. grew its holdings in shares of Personalis by 98.8% during the 4th quarter. American Century Companies Inc. now owns 50,321 shares of the company's stock worth $291,000 after purchasing an additional 25,011 shares during the period. Finally, EntryPoint Capital LLC purchased a new position in shares of Personalis during the 4th quarter worth $275,000. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.